AUS
NZ
UK
CA
USA
IND
Highlights
- In FY25, MSB’s revenue rose 191% YoY to USD 17.2 million, driven by the launch of Ryoncil®.
- Mesoblast secured up to USD 50 million in new funding, aimed at debt reduction and operational support.
- The company targets multiple FDA approvals within 6–12 months, with Ryoncil® underpinning near-term revenue growth.
Mesoblast Limited (ASX:MSB) (NASDAQ:MESO), a biotechnology company developing allogeneic cellular medicines for severe inflammatory conditions and life-threatening inflammatory conditions, reported a significant revenue increase for the 12 months ended 30 June 2025 (FY25). Revenue for the period surged 191% YoY to USD 17.2 million, compared with USD 5.9 million in FY24, primarily driven by the fourth-quarter launch of Ryoncil®.
Despite the sharp increase in revenue, the company recorded a net loss of USD 102.1 million, a 16% rise compared to the USD 88.0 million net loss in FY24. Net cash inflows from financing activities in FY25 reached USD 147.24 million in FY25 against againstUSD 40.25 million in FY24.
Balance Sheet
Mesoblast recently entered into an agreement to access up to USD 50 million (AUD 76.8 million) in funding through convertible notes subscribed to by SurgCenter principals and two existing shareholders. The capital infusion, subject to shareholder approval, is expected to provide greater financial flexibility.
The company plans to use the proceeds to pay down secured debt and support general operations.
Financial indicators presented a mixed picture: the accounts receivable turnover ratio improved to 1.9x in FY25 from 1.1x in FY24, while the debt-to-equity ratio declined to 0.21x from 0.25x. However, the quick ratio of 1.77x fell below the industry median of 1.87x, and the asset turnover ratio of 0.02x remained significantly under the industry median of 0.33x.
Product Pipeline and Outlook
The company anticipates progress in advancing several therapies toward FDA approvals within the next 6 to 12 months, a milestone that could open new revenue streams.
The outlook also highlights Ryoncil® as a key near-term growth driver, with further long-term potential expected from additional therapies under development. Currency fluctuations, regulatory constraints, technology shifts, and inflationary pressures remain important risks to monitor as the company executes its strategy.
Share performance of MSB
Mesoblast shares ended the session at AUD 2.21 per share on 8 September 2025, gaining 4.25% intraday. The stock is up 9.41% over the past week and 25.93% over the past three months, while year-on-year performance shows a sharp increase of 133.86%. Despite these gains, shares are down 4.33% over the past month and have declined 28.71% year-to-date.
The 52-week high of AUD 3.37 was reached on 2 January 2025, while the 52-week low of AUD 0.92 was recorded on 18 September 2024.
Support and Resistance Summary
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 08 September 2025. The reference data in this report has been partly sourced from EODHD/Others.
Technical Indicators Defined:
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.
